Skip to main content
. 2017 Feb 24;12(2):e0171917. doi: 10.1371/journal.pone.0171917

Fig 3. Mean cost (in USD 2012) per patient month for patients initiating ART treatment with CD4 count <200 cells/mm3 in Tanzania for both standard care (control) and the REMSTART trial intervention arms.

Fig 3